As artificial intelligence (AI) and the biopharma industry are key sectors that look set to be fostered by the administration of South Korea’s new president, companies in the country are expected to accelerate moves to adopt AI technologies related to drug discovery and development.
But being a relative latecomer in the area, Korea may need an innovative strategy not seen elsewhere if it is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?